A5048884751- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- RNA Interference and Gene Delivery
- Kawasaki Disease and Coronary Complications
- Cancer Genomics and Diagnostics
- Organ and Tissue Transplantation Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Cardiac pacing and defibrillation studies
- IgG4-Related and Inflammatory Diseases
- Hematopoietic Stem Cell Transplantation
- Cardiac Structural Anomalies and Repair
- Systemic Lupus Erythematosus Research
- Peptidase Inhibition and Analysis
- Cardiac electrophysiology and arrhythmias
- Xenotransplantation and immune response
- Mechanical Circulatory Support Devices
- Parvovirus B19 Infection Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer-related molecular mechanisms research
- Tracheal and airway disorders
- Viral Infections and Immunology Research
- Polyomavirus and related diseases
- Respiratory viral infections research
- Renal Diseases and Glomerulopathies
National Heart Lung and Blood Institute
2022-2025
National Institutes of Health
2023-2025
Digital Research Alliance of Canada
2022
BACKGROUND: Black heart transplant patients are at higher risk of acute rejection (AR) and death than White patients. We hypothesized that this may be associated with levels donor-derived cell-free DNA (dd-cfDNA) mitochondrial DNA. METHODS: The Genomic Research Alliance for Transplantation is a multicenter, prospective, longitudinal cohort study. Sequencing was used to quantitate dd-cfDNA polymerase chain reaction in plasma. AR defined as ≥2R cellular or ≥1 antibody-mediated rejection....
Abstract Background Antibody-mediated rejection (AMR) remains the major risk factor for allograft loss across all solid organ transplantation. Unfortunately, its diagnosis relies on biopsy, an invasive gold standard that often sample unaffected tissue leading to missed diagnosis. Plasma donor-derived cell-free DNA (dd-cfDNA) is noninvasive biomarker has high sensitivity but low specificity AMR This proof-of-concept study assessed utility of chromatin immunoprecipitation (cfChIP) as a...
Objectives/Goals: Lung transplant is a life-saving surgery for patients with advanced lung diseases yet long-term survival remains poor. The clinical features and injury patterns of recipients who die early versus those survive longer term remain undefined. Here, we use cell-free DNA rejection parameters to help elucidate this further. Methods/Study Population: candidacy prioritizes have high mortality risk within 2 years will likely beyond 5 years. We stratified died as death (n = 50)...
BACKGROUND: Heart transplant recipients with donor-specific antibodies (DSAs) have an increased risk for antibody-mediated rejection. However, many patients graft dysfunction and DSA do not evidence of rejection by endomyocardial biopsy (EMB). METHODS: Participants from this prospective, multicenter study underwent serial EMB, echocardiogram, DSA, donor-derived cell-free DNA evaluations. Outcomes were defined as pAMR+ (pAMR≥1) or DSA+/left ventricle (LV) (DSA presence+LVEF drop ≥10% to...
Multisystem inflammatory syndrome in children (MIS-C) is a rare but life-threatening hyperinflammatory condition induced by infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) that causes pediatric COVID-19 (pCOVID-19). The relationship of the systemic tissue injury to pathophysiology MIS-C poorly defined. We leveraged high sensitivity epigenomic analyses plasma cell-free DNA (cfDNA) and cytokine measurements identify spectrum glean mechanistic insights. Compared healthy...
Plasma cell-free DNA levels correlate with disease severity in many conditions. Pretransplant may risk stratify lung transplant candidates for post-transplant complications.
Chronic graft-versus-host disease (cGvHD) is a devastating complication of hematopoietic stem cell transplantation (HSCT). Effective early detection may improve the outcome cGvHD. The potential utility circulating cell-free DNA (cfDNA), sensitive marker for tissue injury, in HSCT and cGvHD remains to be established. Here, cfDNA prospectively collected plasma samples from recipients (including both non-cGvHD) healthy control (HC) subjects were evaluated. Deconvolution methods utilizing...
Introduction: Heart transplant recipients with donor-specific antibodies (DSA) have increased risk for antibody-mediated rejection (AMR). However, many patients graft dysfunction and DSA do not show AMR by endomyocardial biopsy (EMB). Hypothesis: We hypothesized that, similar to EMB-defined AMR, defined as presence + on echocardiography is associated 1) injury via elevated donor-derived cell-free DNA (dd-cfDNA) 2) long-term adverse outcomes. Methods: Adult heart from the Genomic Research...